According to the Zhitong Finance APP, Simcere Pharma (02096) rose more than 12% on high volume, up 12.38% as of the time of publication to 6.99 Hong Kong dollars, with a turnover of 0.233 billion Hong Kong dollars.

On the news front, a recent research report from Zhongjin pointed out that the company's existing business risks are being cleared out, showing relative stability. From October 27th to 30th, the National Medical Insurance Administration conducted a new round of medical insurance negotiations. The company's core products Simbere and Ertumab have undergone two rounds of price negotiations. The bank believes that the current treatment costs are reasonable. The bank expects these two innovative products, Cosela (CDK4/6 inhibitor) and Erbitux (EGFR monoclonal antibody), which are on the negotiation list, to achieve high sales volume next year after being included in medical insurance.

The bank expects the company's recently anticipated innovative drugs: 1) Simbere sublingual tablets, expected to be approved in the next 1-2 months, with the bank estimating potential sales exceeding 1.5 billion yuan in the future; 2) Enzeshu (VEGF monoclonal antibody, ovarian cancer), expected to be approved in 1H25; 3) Kweikao (Darelyserine) for insomnia, a third-generation dual orexin receptor antagonist, expected to be approved in 2025. In addition, innovative drugs such as Lodechibai monoclonal antibody (IL-4) and Madanovir (influenza) are in Phase III clinical trials.